Clinical Trial

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
Protocol Amendment History 43 amendments
This ClinicalTrials.gov record has been amended 43 times since 2021-09-14; most recent amendment 2026-07-24.
Status change: Recruiting → Active, Not Recruiting 2024-05-29
Trial Details
NCT Number NCT05044819
Lead Sponsor Jazz Pharmaceuticals
Collaborators: Jazz Pharmaceuticals Research UK Limited
Conditions Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
Enrollment 154 participants
Start Date 2021-07-07
Primary Completion 2027-08-01 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-28